Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 4
1978 8
1979 6
1980 3
1981 2
1982 6
1983 8
1984 1
1985 7
1986 4
1987 3
1988 7
1989 5
1990 5
1991 9
1992 12
1993 14
1994 15
1995 16
1996 17
1997 20
1998 17
1999 36
2000 36
2001 35
2002 30
2003 44
2004 47
2005 61
2006 72
2007 79
2008 114
2009 160
2010 166
2011 191
2012 223
2013 247
2014 277
2015 311
2016 327
2017 406
2018 446
2019 461
2020 517
2021 622
2022 510
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

5,026 results
Results by year
Filters applied: . Clear all
Page 1
An engineered IL-2 partial agonist promotes CD8+ T cell stemness.
Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, Zhuang X, Mitra S, Lin JX, Gattinoni L, Powell JD, Restifo NP, Garcia KC, Leonard WJ. Mo F, et al. Among authors: liao w. Nature. 2021 Sep;597(7877):544-548. doi: 10.1038/s41586-021-03861-0. Epub 2021 Sep 15. Nature. 2021. PMID: 34526724 Free PMC article.
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.
Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, Zhang Y, Gomez EC, Morreale B, Senchanthisai S, Li J, Turowski SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, Dey P. Alam A, et al. Among authors: liao w. Cancer Cell. 2022 Feb 14;40(2):153-167.e11. doi: 10.1016/j.ccell.2022.01.003. Epub 2022 Feb 3. Cancer Cell. 2022. PMID: 35120601
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH, Wang F. Wang ZX, et al. Among authors: liao w. Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3. Cancer Cell. 2022. PMID: 35245446 Clinical Trial.
Retraction Note: TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways.
Yang RW, Zeng YY, Wei WT, Cui YM, Sun HY, Cai YL, Nian XX, Hu YT, Quan YP, Jiang SL, Wang M, Zhao YL, Qiu JF, Li MX, Zhang JH, He MR, Liang L, Ding YQ, Liao WT. Yang RW, et al. Among authors: liao wt. J Exp Clin Cancer Res. 2021 Sep 1;40(1):277. doi: 10.1186/s13046-021-02079-2. J Exp Clin Cancer Res. 2021. PMID: 34470659 Free PMC article. No abstract available.
5,026 results